Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

M. Lee; Baek‐Yeol Ryoo; Chih‐Hung Hsu; Kazushi Numata; Stacey Stein; Wendy Verret; Stephen P. Hack; Jessica Spahn; B. Liu; Hesham Abdullah; Ruth He; Ki Hoon Lee

doi:10.1093/annonc/mdz394.030

Keywords

MedicineAtezolizumabClinical endpointOncologyInternal medicineAdverse effectHepatocellular carcinomaClinical trialCancerNivolumabImmunotherapy

Affiliated Institutions

Related Publications

Advances in immunotherapy for hepatocellular carcinoma

Bruno Sangro , Pablo Sarobe , Sandra Hervás‐Stubbs +1 more

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 co...

2021 Nature Reviews Gastroenterology & Hep... 1220 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet , Florian Castet , Mathias Heikenwälder +6 more

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patie...

2021 Nature Reviews Clinical Oncology 1590 citations

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J. Overman , Sara Lonardi , Francesco Leone +16 more

519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair...

2017 Journal of Clinical Oncology 69 citations

Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma

Valérie Boige , David Malka , Abderrahmane Bourredjem +9 more

Abstract Objective. Hepatocellular carcinoma (HCC) is a highly vascularized tumor in which neoangiogenesis contributes to growth and metastasis. We assessed the safety, efficacy...

2012 The Oncologist 131 citations

Publication Info

Year: 2019
Type: article
Volume: 30
Pages: v875-v875
Citations: 79
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    M. Lee, 
                                
                                    Baek‐Yeol Ryoo, 
                                
                                    Chih‐Hung Hsu
                                
                                et al.
                            
                            (2019). 
                            Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). 
                            Annals of Oncology
                            , 30
                            
                            , v875-v875.
                            https://doi.org/10.1093/annonc/mdz394.030

Identifiers

DOI: 10.1093/annonc/mdz394.030